All I am saying is GMP does not equal a license to distribute Cannepil. I accept that its a step required to move to the next stage and that a similar product produced by another company is already approved for sale. That still does not mean that Cannepil has approval yet.
My other point was to do with misleading announcements from the BOD some months ago which read like it was already being distributed.
Revenue will always be the key as I have said many times. Let’s hope that the BOD doesn’t stuff things up from here. Based on previous Ann’s the market will not re rate this company until it sees hard evidence of revenues.
MXC Price at posting:
6.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
